Page 2 - புதியது இங்கிலாந்து இதழ் மருந்து News Today : Breaking News, Live Updates & Top Stories | Vimarsana

If the single-dose vaccine is found to be effective, the company will apply for an emergency use authorisation to the US Food and Drug Administration, among other regulatory bodies, for it to be made subsequently. Whereas other vaccines are also on trial across the globe, researchers in the study have revealed that the JNJ-78436735 would be easier to administer. The dose will also reach out to more people. For example, 500 doses will be administered to 500 people. Findings of the vaccine that brought about 40,000 participants were published in the New England Journal Medicine on January 13, 2021. During trial, the vaccine was found to provide an immune response that lasted at least 71 days among participants in the age brackets of 18 and 55.

Janssen covidUniversity of oxfordWellcome trust in kilifiDrug administrationKenya medical research instituteJanssen pharmaceutical companies of johnsonJohnson companyCompany covidAstrazeneca the universityKenya medical research institute wellcome trustJanssen pharmaceutical companiesNew england journal medicineபல்கலைக்கழகம் ஆஃப் ஆக்ஸ்ஃபர்ட்கேந்ய மருத்துவ ஆராய்ச்சி நிறுவனம்ஜான்சன் மருந்து நிறுவனங்கள் ஆஃப் ஜான்சன்ஜான்சன் நிறுவனம்